Genzyme Corporation

Genzyme Coporation

Julie Bird

Huawei Qiu

Clark Qun Pan

Clark Pan

A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.

Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificity

An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificity

A modified IgG antibody binds and neutralizes TGF&#x3b2;1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG anti-body is useful in therapeutic and diagnostic applications.

Modified-IgG antibodies that bind transforming growth factor-BETA1 with high affinity, avidity and specificity

A modified IgG antibody binds and neutralizes TGF&#x3b2;1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications.

Modified-IgG antibodies that bind transforming growth factor-&#x3b2;1 with high affinity, avidity and specificity

An scFv-Fc dimer binds and neutralizes TGF&#x3b2;1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF&#x3b2;1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.

Growing community of inventors

Bridgewater, NJ, United States of America

Julie Bird